Title:  Method of treating a bacterial infection comprising administering amoxycillin

United States Patent:  6,294,199

Assignee:  Beecham Pharmaceuticals (Pte) Limited (Singapore, SG)

Filed:  April 6, 2000

Bacterial infections may be treated using a high dosage regimen of amoxycillin. Preferably, the dosage is provided by a bilayer tablet.

SUMMARY OF THE INVENTION

The present invention relates to a method of treating bacterial infections in humans which comprises administering thereto a therapeutically effective amount of amoxycillin in the range 1900 to 2600 mg, at a dosage regimen/interval of about 12 hours. Suitably, the infection is caused by the organisms S pneumoniae (including Drug Resistant and Penicillin Resistant S pneumoniae), H influenzae M catarrhalis and/or S Pyogenes.

The present invention also relates to a modified release pharmaceutical formulation comprising amoxycillin in which a first part of amoxycillin are formulated with pharmaceutically acceptable excipients which allow for immediate release of the first part of amoxycillin, to form an immediate release phase, and further comprising a second part of amoxycillin formulated with pharmaceutically acceptable excipients which allow for slow release of the second part of amoxycillin, to form a slow release phase.

The present invention also relates to an immediate release pharmaceutical tablet formulation comprising 1000 mg.+-.5% amoxycillin in combination with pharmaceutically acceptable excipients or carriers.

The present invention also relates to an immediate release pharmaceutical formulation in the form of a single dose sachet comprising 2000, 2250 or 2500 mg.+-.5% amoxycillin, or the corresponding half quantities thereof, in combination with pharmaceutically acceptable excipients or carriers.

Claim 1 of 15 Claims

What is claimed is:

1. A method of treating a bacterial infection in a human in need thereof which method comprises administering to said human a dosage of a therepeutically effective amount of amoxycillin in the range of 1900 to 2600 mg, at a dosage regimen interval of about 12 h, and wherein the infection is caused by the organism S pneumoniae (including Drug Resistant and Penicillin Resistant S pneumoniae), H influenzae, M catarrhalis and/or S pyogenes.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.